Europe Lung Cancer Screening Market Forecast to 2030
Europe Lung Cancer Screening Market Forecast to 2030 – Regional Analysis – by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Lung Cancer Incidences Fuel Europe lung cancer screening market.
Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs.
As per research conducted by the cancer journal Annals of Oncology, around 1,261,990 cancer patients are expected to die in 2023 in the EU region. Lung cancer death rates would increase by over 1% to 13.6 per 100,000. As more UK women started smoking earlier than those in the EU, there will be a 13.8% decrease in the death rate from lung cancer among women in the UK, although the death rate of 16.2 per 100,000 is still higher than among women in the EU. In the UK, lung cancer currently claims more per 100,000 than breast cancer, which claims 13.5 per 100,000.
When the researchers particularly examined lung cancer death rates in five EU nations in addition to the UK, they discovered that while rates are expected to decline for men in the most populous six nations (France, Germany, Italy, Poland, and Spain), they will increase for women in France, Italy, and Spain by about 14%, 5.6%, and 5%, respectively. The researchers discovered that among women in various age groups, expected mortality rates from lung cancer decreased among those between the ages of 25 and 64 but increased among those between the ages of 65 and over 75, leading to an increase overall. Also, according to the National Center for Biotechnology Information (NCBI), each year, ~41,000 new diagnoses of lung cancers and 34,000 deaths are recorded in Italy. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.
Europe Lung Cancer Screening Market Overview
The Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side lung cancer screening and diagnosis among people. Also, rising government support for screening has led to the further growth of the market.
The increasing prevalence of lung cancer has made its screening extremely important for early detection. Lung cancer screening is suggested for older adults who are long-time smokers and do not have any symptoms related to lung cancer. Physicians use a low-dose computerized tomography (LDCT) scan or X-ray for screening.
According to an article titled “Lung Cancer in Germany,” published in the Journal of Thoracic Oncology, in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. In men, lung cancer ranks second after cardiovascular disease, accounting for 6.5% of all-cause mortality. With an age-standardized incidence rate of 52.1 and 32.7 and (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly
Europe Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)
Europe Lung Cancer Screening Market Segmentation
The Europe lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.
Based on cancer type, the Europe lung cancer screening market is segmented into non–small cell lung cancer (NSCLC), and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the Europe lung cancer screening market in 2022.
Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the Europe lung cancer screening market in 2022.
Based on age group, the Europe lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Europe lung cancer screening market in 2022.
Based on end user, the Europe lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Europe lung cancer screening market in 2022.
Based on country, the Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe lung cancer screening market in 2022.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, and Intelerad Medical Systems are some of the leading companies operating in the Europe lung cancer screening market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ Research, the Europe lung cancer screening market was valued at US$ 593.25 million in 2022 and is expected to reach US$ 1,090.99 million by 2030, registering a CAGR of 7.9% from 2022 to 2030. Rising lung cancer incidences and increasing government are the critical factors attributed to the Europe lung cancer screening market.
Several countries face challenges with lung cancer screening programs. On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.
Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the Europe Lung Cancer Screening Market during the forecast period.
On the contrary, high cost of lung cancer screening hampers the Europe lung cancer screening market.
Based on cancer type, the Europe lung cancer screening market is segmented into non–small cell lung cancer (NSCLC)
and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 79.7% share of Europe lung cancer screening market in 2022, amassing US$ 472.65 million. It is projected to garner US$ 855.61 million by 2030 to expand at 7.7% CAGR during 2022–2030.
Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. The low dose computed tomography (LDCT) segment held 44.6% share of Europe lung cancer screening market in 2022, amassing US$ 264.69 million. It is projected to garner US$ 501.92 million by 2030 to expand at 8.3% CAGR during 2022–2030.
Based on age group, the Europe lung cancer screening market is segmented into 50 and older and below 50. The 50 and older segment held 89.3% share of Europe lung cancer screening market in 2022, amassing US$ 529.64 million. It is projected to garner US$ 967.31 million by 2030 to expand at 7.8% CAGR during 2022–2030.
Based on end user, the Europe lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 43.4% share of Europe lung cancer screening market in 2022, amassing US$ 257.55 million. It is projected to garner US$ 456.06 million by 2030 to expand at 7.4% CAGR during 2022–2030.
Based on country, the Europe lung cancer screening market has been categorized into the Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 25.6% share of Europe lung cancer screening market in 2022. It was assessed at US$ 151.93 million in 2022 and is likely to hit US$ 275.37 million by 2030, exhibiting a CAGR of 7.7% during the forecast period.
Key players operating in the Europe Lung Cancer Screening market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, Siemens AG, and bioAffinity Technologies, Inc among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Lung Cancer Screening Market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Europe Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Research Team Report Guidance
1.3 Market Segmentation
1.3.1 Europe Lung Cancer Screening Market – by Technology
1.3.2 Europe Lung Cancer Screening Market – by Cancer Type
1.3.3 Europe Lung Cancer Screening Market – by Age Group
1.3.4 Europe Lung Cancer Screening Market – by End User
1.3.5 Europe Lung Cancer Screening Market – by Country
2. Europe Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. Europe Lung Cancer Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Lung Cancer Incidences
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis
6. Europe Lung Cancer Screening Market – Europe Analysis
6.1 Europe Lung Cancer Screening Market Revenue Forecast and Analysis
7. Europe Lung Cancer Screening Market – Revenue and Forecast to 2028 – By Cancer Type
7.1 Overview
7.2 Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
8.2.1 Overview
8.2.2 Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
8.3.1 Overview
8.3.2 Chest X-ray: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
8.4.1 Overview
8.4.2 Liquid Biopsy: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
9. Europe Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 & Older
9.2.1 Overview
9.2.2 & Older: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
9.3.1 Overview
9.3.2 Below 50: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Hospitals
10.2.1 Overview
10.2.2 Hospitals: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
11. Europe Lung Cancer Screening Market – Revenue and Forecast to 2028 – Country Analysis
11.1 Europe: Europe Lung Cancer Screening Market Overview
11.1.1.1 Germany: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Germany: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.3 Germany: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.1.4 Germany: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.5 Germany: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.1.6 Germany: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 UK: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 UK: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.3 UK: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.2.4 UK: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.5 UK: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.2.6 UK: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 France: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 France: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.3 France: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.3.4 France: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.5 France: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.3.6 France: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.4 Italy: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Italy: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.3 Italy: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.4.4 Italy: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.5 Italy: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.4.6 Italy: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.5 Spain: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 Spain: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.3 Spain: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.5.4 Spain: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.5 Spain: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.5.6 Spain: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.6 Rest of Europe: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.3 Rest of Europe: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.6.4 Rest of Europe: Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.5 Rest of Europe: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.6.6 Rest of Europe: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
12. Europe Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 2. Germany Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 3. Germany Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 4. Germany Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 6. UK Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 7. UK Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 9. France Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 10. France Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 11. France Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 12. France Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Italy Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 14. Italy Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 17. Spain Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 18. Spain Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Europe Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 22. Rest of Europe Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Recent Growth Strategies in the Europe Lung Cancer Screening Market
Table 26. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Lung Cancer Screening Market Segmentation
Figure 2. Europe Lung Cancer Screening Market, by Country
Figure 3. Europe Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in Europe Lung Cancer Screening Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Europe Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. Europe Lung Cancer Screening Market – Revenue Forecast and Analysis – 2020-2030
Figure 10. Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non–Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Lung Cancer Screening Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26. Europe Lung Cancer Screening Market Revenue Share, by Country, (2022 & 2030)
Figure 27. Germany: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. UK: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. France: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Italy: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. Spain: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Rest of Europe: Europe Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
The List of Companies – Europe Lung Cancer Screening Market
o Nuance Communications Inc
o GE HealthCare Technologies Inc
o Medtronic Plc
o Canon Medical Systems Corp
o Koninklijke Philips NV
o Siemens AG
You must be logged in to post a review.
Reviews
There are no reviews yet.